Quick Answer
Silence Therapeutics plc reported Operating Income of -$91.08 million for fiscal year 2025.
Silence Therapeutics plc Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$91.08M | -43.8% |
| 2024 | -$63.32M | +1.7% |
| 2023 | -$64.38M | -5.5% |
| 2022 | -$61.04M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$26.24M | +12.5% | -9.5% |
| June 30, 2025 | -$23.96M | -2.5% | +15.6% |
| March 31, 2025 | -$28.41M | -409.0% | +5.3% |
| September 30, 2024 | -$30.00M | — | -28.3% |
| June 30, 2024 | -$23.39M | — | -319.1% |
| March 31, 2024 | -$5.58M | — | — |
- Silence Therapeutics plc showed a decrease of -43.8% in Operating Income compared to the prior fiscal year.
- Over the 2022–2025 period, Silence Therapeutics plc’s operating income has declined by 49.2% (from -$61.04 million to -$91.08 million).
- The most recent figure is from Silence Therapeutics plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: